Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Apellis Pharmaceuticals (APLS) over the last 5 years, with Q3 2025 value amounting to $24.5 million.

  • Apellis Pharmaceuticals' Cost of Revenue fell 2689.75% to $24.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.4 million, marking a year-over-year increase of 1714.75%. This contributed to the annual value of $117.7 million for FY2024, which is 10120.15% up from last year.
  • Apellis Pharmaceuticals' Cost of Revenue amounted to $24.5 million in Q3 2025, which was down 2689.75% from $13.6 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Cost of Revenue registered a high of $40.9 million during Q4 2024, and its lowest value of $51000.0 during Q4 2021.
  • Its 5-year average for Cost of Revenue is $15.0 million, with a median of $13.6 million in 2025.
  • Its Cost of Revenue has fluctuated over the past 5 years, first skyrocketed by 1011829.27% in 2023, then crashed by 4101.3% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Cost of Revenue (Quarter) stood at $51000.0 in 2021, then skyrocketed by 5635.29% to $2.9 million in 2022, then surged by 580.75% to $19.9 million in 2023, then surged by 105.18% to $40.9 million in 2024, then tumbled by 39.96% to $24.5 million in 2025.
  • Its last three reported values are $24.5 million in Q3 2025, $13.6 million for Q2 2025, and $34.4 million during Q1 2025.